Table 3 Detailed characteristics of the autoimmune disease group
From: SARS-COV-2 vaccine responses in renal patient populations
N = 223 | |
|---|---|
Diagnosis (Number (%)) | |
- ANCA-associated vasculitis | 133 (60) |
- Large vessel vasculitis | 11 (5) |
- Systemic lupus erythematosus | 27 (12) |
- Behcet’s disease | 17 (8) |
- Othera | 25 (16) |
GFR (ml/min/m2) (median (IQR)) | 84 (56–90) |
Rituximab (Number (%)) | |
- Received within 6 months | 70 (31) |
- Received within 12 months | 108 (48) |
- Received within 5 years | 128 (57) |
Days since last rituximab dose (median (IQR) | 162 (110–275) |
IV cyclophosphamide (Number (%)) | |
- Received within 6 months | 76 (34) |
- Received within 12 months | 103 (46) |
Days since last IV cyclophosphamide dose (median (IQR)) | 79 (19–177) |
Other concurrent immunosuppressive agents (Number (%)) | |
- Mycophenolate mofetil | 33 (15) |
- Azathioprine | 17 (8) |
- Methotrexate | 13 (6) |
- Anti-TNF alpha therapy | 9 (4) |
- Belimumab | 11 (5) |
- Tocilizumab | 4 (2) |
Concurrent prednisolone (Number (%)) | 111 (50) |
- Total daily dose (mg) (median (IQR)) | 2 (0–5) |